论文部分内容阅读
脑卒中是心房颤动(房颤)最危险而严重的并发症,而抗凝治疗可显著降低房颤患者的卒中风险,改善患者预后,因而成为房颤治疗的核心策略之一。华法林于20世纪50年代开始应用于房颤抗凝,其疗效可靠,但治疗窗窄、起效慢、失效时间长、个体间的有效剂量差异大(部分与患者的基因分型有关)、药物和食物影响因素多,并需要定期监测抗凝强度以调整华法林的用量,故导致其在临床上的应用受到较多限制[1]。随着医疗技术的进展,近年来
Stroke is the most dangerous and serious complication of atrial fibrillation (AF). Anticoagulant therapy can significantly reduce the risk of stroke and improve the prognosis of patients with atrial fibrillation. Therefore, it is one of the core strategies for the treatment of AF. Warfarin has been used in the anticoagulation of atrial fibrillation in the 1950s. The curative effect is reliable. However, the therapeutic window is narrow, the onset of action is slow, the lapse of time is long, and the effective dose varies greatly between individuals (some are related to the patient’s genotyping) , Drugs and food affect many factors, and the need for regular monitoring of anticoagulant to adjust the amount of warfarin, it led to its clinical application is more limited [1]. With the progress of medical technology, in recent years